Latest From Alcobra Ltd.
The unexpected firing of Arcturus CEO Joseph Payne kicked off a bitter public battle for control of the RNA therapeutics firm after a reverse merger with Alcobra in November. The dispute now settled, the new board has reinstated Payne at Arcturus' helm.
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
Daiichi teams with Glycotope on an antibody-drug conjugate for cancer, while Alector will partner with AbbVie to research antibody targets for Alzheimer’s disease.
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
- Therapeutic Areas
- Neurology, Nervous System
- Middle East
- Parent & Subsidiaries
- Alcobra Ltd.
- Senior Management
Tomer Berkovitz, PhD, CFO
Jonathan Rubin, MD, CMO
David C Baker, Chief Commercial Officer
- Contact Info
Phone: 72-220 4661
132 Derech Menachem Begin
Tel Aviv, 6701101
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.